31,435 Shares in Baxter International Inc. $BAX Acquired by CenterBook Partners LP

CenterBook Partners LP purchased a new position in Baxter International Inc. (NYSE:BAX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 31,435 shares of the medical instruments supplier’s stock, valued at approximately $754,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Jones Financial Companies Lllp purchased a new stake in shares of Baxter International in the 2nd quarter worth $26,000. CYBER HORNET ETFs LLC lifted its position in Baxter International by 52.4% during the second quarter. CYBER HORNET ETFs LLC now owns 2,153 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 740 shares in the last quarter. Community Bank N.A. purchased a new position in Baxter International during the second quarter valued at $46,000. Versant Capital Management Inc lifted its position in Baxter International by 552.2% during the second quarter. Versant Capital Management Inc now owns 2,413 shares of the medical instruments supplier’s stock valued at $51,000 after purchasing an additional 2,043 shares in the last quarter. Finally, EFG International AG bought a new stake in Baxter International during the second quarter valued at about $67,000. Hedge funds and other institutional investors own 90.19% of the company’s stock.

Baxter International Stock Up 0.0%

BAX opened at $26.42 on Wednesday. The stock has a market cap of $13.67 billion, a price-to-earnings ratio of 13.61, a price-to-earnings-growth ratio of 3.89 and a beta of 0.68. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.19 and a current ratio of 1.79. The firm’s fifty day moving average is $24.51 and its 200 day moving average is $21.57. Baxter International Inc. has a fifty-two week low of $15.73 and a fifty-two week high of $30.00.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.52 by $0.06. The business had revenue of $2.98 billion during the quarter, compared to analyst estimates of $2.91 billion. Baxter International had a positive return on equity of 16.23% and a negative net margin of 6.23%. Baxter International’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.69 EPS. On average, sell-side analysts forecast that Baxter International Inc. will post 2.10 earnings per share for the current fiscal year.

Baxter International Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Friday, November 27th will be given a dividend of $0.01 per share. The ex-dividend date is Friday, November 27th. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. Baxter International’s dividend payout ratio (DPR) is currently -2.84%.

Analysts Set New Price Targets

A number of analysts have commented on the company. Stifel Nicolaus upped their price target on Baxter International from $19.00 to $24.00 and gave the stock a “hold” rating in a research report on Tuesday, July 28th. Wall Street Zen raised Baxter International from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. The Goldman Sachs Group lifted their price objective on Baxter International from $19.00 to $21.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. UBS Group boosted their price objective on Baxter International from $19.00 to $25.00 and gave the company a “hold” rating in a research note on Tuesday, July 28th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $25.00 target price on shares of Baxter International in a report on Thursday, October 29th. One analyst has rated the stock with a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Baxter International has an average rating of “Reduce” and a consensus price target of $23.27.

About Baxter International

Baxter International is a global healthcare company that develops and supplies products used in hospitals, clinics and other care settings. Its offerings include intravenous solutions and administration sets, infusion pumps, medication-delivery systems, and products for surgical and hospital care. The company also provides patient-monitoring and connected-care technologies, including products associated with Hillrom, which Baxter acquired in 2021. Its products and services support healthcare professionals and patients in countries around the world.